Physician profile
Charles K Everett
NPI 1316147382
$4,258.69
in general payments reported to CMS, 2019-2025
34 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $271 · 2021: $75.79 · 2022: $427 · 2023: $700 · 2024: $815 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,005.72 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $834.12 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Astrazeneca Pharmaceuticals Lp | $581.24 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Insmed, INC. | $173.25 | 2019-2025 | Brinsupri, Arikayce |
| Janssen Pharmaceuticals, INC | $119.32 | 2020-2023 | Xarelto |
| Pulmonx Corporation | $113.51 | 2020-2025 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Medtronic Vascular, INC. | $112.64 | 2019 | |
| Merck Sharp & Dohme LLC | $108.32 | 2019-2025 | Zerbaxa, Capvaxive, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $98.29 | 2019-2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $96.58 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $86.65 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $77.25 | 2022-2024 | Cuvitru, Hyqvia |
| Amgen INC. | $75.46 | 2024-2025 | Tezspire, Tavneos |
| Pfizer INC. | $66.73 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $59.66 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $56.61 | 2023-2025 | Tyvaso, Orenitram, Tyvaso |
| Genzyme Corporation | $54.99 | 2019-2025 | |
| Genentech USA, INC. | $52.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.04 | 2019-2024 | |
| Electromed, INC. | $47.58 | 2023 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $43.00 | 2019-2022 | |
| Baxter Healthcare | $40.83 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $40.19 | 2019 | |
| Stryker Corporation | $34.61 | 2025 | Flowtriever |
| Sanofi Pasteur INC. | $27.87 | 2019 | |
| Lilly USA, LLC | $26.81 | 2025 | Mounjaro, Zepbound |
| Advanced Respiratory, INC | $26.78 | 2019 | |
| Erbe USA INC | $26.00 | 2025 | Cryo2 |
| Grifols USA, LLC | $23.18 | 2024 | Prolastin-C Liquid |
| Mayne Pharma Commercial LLC | $22.82 | 2020 | |
| Resmed Corp | $21.75 | 2019 | |
| Gilead Sciences, INC. | $20.52 | 2019 | |
| Circassia INC. | $19.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.